Novo Nordisk’s Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency

 Novo Nordisk’s Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency

Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B

Shots:

  • The approval is based on REAL 1 study assessing Sogroya (10 mg/ 1.5 mL (6.7 mg/mL) vs PBO for 35wks. in adults patients with growth hormone deficiency
  • The US FDA ahs approved the BLA of the therapy for the replacement of endogenous growth hormone in adults with GHD
  • Sogroya is a prescription medicine containing GH and is used to treat adults who do not make enough growth hormone. Efficacy and safety in children are not known

Click here ­to­ read full press release/ article | Ref: Businessnewswire | Image: Businessnewswire

Parag Narang

Related post